目的 评价2011-2016年天津市肿瘤医院乳腺癌内分泌治疗药物的使用情况。方法 调取天津市肿瘤医院2011-2016年乳腺癌内分泌治疗药物的相关用药信息，对药品使用金额、用药频度（DDDs）、日均费用（DDC）及药品排序比（B/A）进行统计分析。结果 2011-2016年天津市肿瘤医院乳腺癌内分泌治疗药物的临床应用呈逐年上升趋势。芳香酶抑制剂（AIs）使用金额的占比大于70%。各类药品的DDDs整体亦呈现增长趋势，依西美坦（进口）增幅最大。各类药品的DDC值稳中有降，大部分乳腺癌内分泌治疗药物的B/A值接近于1.00，使用金额和DDDs同步性较好。结论 天津市肿瘤医院乳腺癌内分泌药物使用基本合理，符合安全、有效、经济、方便的原则。

Objective To investigate the utilization of breast cancer endocrine therapy drugs in Tianjin Cancer Hospital from 2011 to 2016. Methods The utilization information of breast cancer endocrine therapy drugs in Tianjin Cancer Hospital from 2011 to 2016 was extracted, and the consumption sum of drugs, defined daily doses (DDDs), defined daily cost (DDC), and drug sequence ratio (B/A) were analyzed statistically. Results From 2011 to 2016, clinical application of endocrine therapy for breast cancer increased year by year. The proportion of AIs was more than 70%. DDDs of various drugs also showed an overall trend, while ethoxetron (import) increased the most. DDC values of all kinds of drugs were steadily lower. Most of the breast cancer endocrine therapy drugs B/A was close to 1.00, indicating that the synchronism was better. Conclusion The utilization of breast cancer endocrine therapy in Tianjin Cancer Hospital is reasonable, according with the principle of safety, effectiveness, economy, and convenience.